This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Antioestrogens

Authoring team

Antioestrogens are used in the hormonal treatment of breast cancer. The gold standard is tamoxifen which is primarily an oestrogen receptor antagonist with some agonist acitivity.

Tamoxifen taken for 5 years following surgical treatment is a standard part of the treatment regime for postmenopausal women with hormone-receptor-positive breast cancer. If used in this context then tamoxifen:

  • increases the proportion of women who survive for at least 10 years from about 50% to 60% among those with lymph-node involvement
  • increases the proportion of women who survive for at least 10 years without lymph-node involvement from about 73% to 79%
  • almost halves the risk of development of cancer in the contralateral breast

Reference:

  1. Drug and Therapeutics Bulletin (2003), 41 (8), 57-59.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.